Dapagliflozin on Blood Pressure Variability and Ambulatory Arterial Stiffness Index in Hypertension
Effect of Dapagliflozin on the Blood Pressure Variability and the Ambulatory Arterial Stiffness Index in Individuals With Stage I Hypertension Without Diabetes Mellitus
Sponsor: University of Guadalajara
Listed as NCT03592667, this PHASE4 trial focuses on Hypertension and remains ongoing. Sponsored by University of Guadalajara, it has been updated 9 times since 2019, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Nov 2022 — Jul 2024 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Jan 2021 — Nov 2022 [monthly]
Recruiting PHASE4
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE4
Status: Enrolling By Invitation → Recruiting
▶ Show 4 earlier versions
-
May 2020 — Sep 2020 [monthly]
Enrolling By Invitation PHASE4
-
Apr 2020 — May 2020 [monthly]
Enrolling By Invitation PHASE4
-
Aug 2019 — Apr 2020 [monthly]
Enrolling By Invitation PHASE4
-
Aug 2018 — Aug 2019 [monthly]
Enrolling By Invitation PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of Guadalajara
For direct contact, visit the study record on ClinicalTrials.gov .